Side effects (any reported throughout the intervention period) (ALL) · pregnant women
It is very uncertain whether (Maternal outcomes) Any supplements containing iron changes side effects (any reported throughout the intervention period) (ALL) compared with same supplements without iron or no treatment/placebo (no iron or… (very low certainty).
1 finding from 1 review
Intervention not reported
At least 50% of maximum pain relief over 4 to 6 hours · Adults with acute pain
The intervention leads to higher at least 50% of maximum pain relief over 4 to 6 hours (high certainty).
1 finding from 1 review
Intervention not reported
Participants remedicating within 8 hours · Adults with acute pain
The intervention leads to lower participants remedicating within 8 hours (high certainty).
1 finding from 1 review
Intervention not reported
Participants with at least 1 adverse event (all diclofenac potassium doses, 25 mg to 100 mg) · Adults with acute pain
The intervention showed no clear difference in participants with at least 1 adverse event (all diclofenac potassium… (moderate certainty).
1 finding from 1 review
Intervention not reported
Participants with a serious adverse event (whole data set) · Adults with acute pain
1 finding from 1 review
Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg probably leads to higher remission (combined clinical and endoscopic remission) compared with placebo (moderate certainty).
1 finding from 1 review
Endoscopic improvement (dichotomous) · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in endoscopic improvement compared with placebo (moderate certainty).
1 finding from 1 review
Histologic remission · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in histologic remission compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide MMX® 6 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Endoscopic improvement (dichotomous) · Adult patients with active ulcerative colitis
Budesonide 10 mg showed no clear difference in endoscopic improvement compared with prednisolone 40 mg (low certainty).
1 finding from 1 review
Endoscopic remission · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide 10 mg changes endoscopic remission compared with prednisolone 40 mg (very low certainty).
1 finding from 1 review
Histologic remission · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide 10 mg changes histologic remission compared with prednisolone 40 mg (very low certainty).
1 finding from 1 review
Adverse event ‐ Reduction in plasma cortisol below lower reference limit · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide 10 mg changes adverse event ‐ Reduction in plasma cortisol below lower reference… compared with prednisolone 40 mg (very low certainty).
1 finding from 1 review
Study Withdrawals · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide 10 mg changes study withdrawals compared with prednisolone 40 mg (very low certainty).
1 finding from 1 review
Clinical improvement · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in clinical improvement compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide 10 mg changes withdrawal due to adverse event compared with prednisolone 40 mg (very low certainty).
1 finding from 1 review
Clinical remission · Adult patients with active ulcerative colitis
Budesonide probably leads to lower clinical remission (ITT analysis) compared with mesalamine (moderate certainty).
1 finding from 1 review
Endoscopic improvement (dichotomous) · Adult patients with active ulcerative colitis
Budesonide probably leads to lower endoscopic improvement Gross 2011 compared with mesalamine (moderate certainty).
1 finding from 1 review